FREE FEDEX 2-DAY SHIPPING OVER $200Same-Day Dispatch Before 1 PM ETThird-Party TestedBatch COAs Available
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
Peptide Pilots
Log in
NeuropeptidesEvidence qualityPublication patterns

Reading a Regional Literature: Semax, Selank and DSIP Research in Context

Three neuropeptides share an unusual research profile: substantial published output concentrated in one region, limited independent replication, and endpoints that are hard to measure objectively.

By Samantha Lundqvist, MSc, Biochemistry8 min read

This article summarises published scientific literature for laboratory professionals. It is not medical advice and does not describe human or veterinary use. All materials supplied by Peptide Pilots are for controlled laboratory research only.

Key takeaways

  • Semax, Selank and DSIP share an appraisal problem: much of the primary literature is regionally published and hard to independently verify.
  • Their reported endpoints — cognition, anxiety, sleep architecture — resist objective measurement, which widens the confidence interval on every claim.
  • DSIP is the clearest cautionary case, where an early named effect was not reproduced by later controlled work.

The shared appraisal problem

Semax is a synthetic analogue of the ACTH 4-10 fragment, Selank a synthetic analogue of the immunomodulatory peptide tuftsin, and DSIP a nonapeptide first isolated from rabbit cerebral venous blood in sleep experiments. Their literatures share a structural feature that matters more than their pharmacology: a large proportion of the primary work was published in a single research tradition, often in journals with limited indexing outside that region, and much of it has not been independently replicated elsewhere.

This is a reason for caution in appraisal, not a claim that the work is wrong. The correct handling is to state the concentration of the evidence base explicitly and avoid presenting single-region findings as settled consensus.

Endpoints that resist objective measurement

Cognitive, anxiolytic and sleep endpoints are among the hardest to measure reproducibly. Rodent anxiety assays are sensitive to lighting, handling and time of day; sleep architecture depends on scoring conventions and on whether electroencephalography was used at all; and human cognitive test batteries carry substantial practice effects when repeated. Effects reported without blinding and without a prespecified primary endpoint should be read as preliminary regardless of the reported significance level.

  • Was the outcome measured instrumentally, or scored by an observer who knew the allocation?
  • Was a primary endpoint declared before data collection?
  • Is the full-text methods section available in translation, or only an abstract?
  • Has any group outside the originating tradition reproduced the finding?

DSIP as a cautionary case

DSIP is instructive because its defining property — sleep induction — proved difficult to reproduce consistently after the original isolation work, and its endogenous role remains unresolved decades later. A peptide named for an effect is not evidence that the effect is robust; the name records what the original investigators believed they had observed.

Compound pages

The research library entries for all three set out identifiers, the reported mechanisms by evidence tier, study tables with citations, and a limitations section that names the publication-base problem directly.

Related research

References

  1. Ashmarin, I. P., et al. (1997). Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and hydrophobic radicals. Neuroscience Research Communications. View source
  2. Kozlovskii, I. I., & Danchev, N. D. (2003). The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology. View source
  3. Schoenenberger, G. A., & Monnier, M. (1977). Characterization of a delta-electroencephalogram-sleep-inducing peptide. Proceedings of the National Academy of Sciences. View source

Frequently asked questions

Both peptides were developed at Russian research institutes — Semax at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank at the Zakusov Institute of Pharmacology — and most of the primary studies were conducted and published within that research ecosystem. English-language independent replications are comparatively scarce, which is a real limitation when assessing the evidence.

Delta sleep-inducing peptide is a nonapeptide first isolated in the 1970s and named for early observations of effects on sleep-related EEG activity in animal models. Subsequent research has produced mixed findings, and its mechanisms and physiological role remain an open research question rather than an established pharmacology.

With the same methodological standards applied to any literature — checking randomisation, blinding, sample size and replication — plus extra caution for translation quality and the absence of independent Western replications. Regulatory status also differs by jurisdiction; none of these peptides is an approved drug in the United States or EU, and material is supplied for laboratory research only.